Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Oral Anticoagulants Market

ID: MRFR/HC/6249-CR
150 Pages
Vikita Thakur
Last Updated: April 24, 2026

Oral Anticoagulants Market Research Report Information By Product (Novel Oral Anticoagulant and Warfarin), By Disease Indication (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Heart Attacks), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), And By Region (Europe, Asia-Pacific, North America, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Product (USD Billion) | |
      1. 4.1.1 Novel Oral Anticoagulants | |
      2. 4.1.2 Warfarin |
    2. 4.2 Healthcare, BY Disease Indication (USD Billion) | |
      1. 4.2.1 Atrial Fibrillation | |
      2. 4.2.2 Deep Vein Thrombosis (DVT) | |
      3. 4.2.3 Pulmonary Embolism (PE) | |
      4. 4.2.4 Heart Attacks |
    3. 4.3 Healthcare, BY Distribution Channel (USD Billion) | |
      1. 4.3.1 Hospital Pharmacies | |
      2. 4.3.2 Retail Pharmacies | |
      3. 4.3.3 Online Pharmacies |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bristol-Myers Squibb (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Bayer (DE) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Johnson & Johnson (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Pfizer (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AstraZeneca (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Daiichi Sankyo (JP) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Sanofi (FR) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Roche (CH) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Merck & Co. (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY PRODUCT |
    7. 6.4 US MARKET ANALYSIS BY DISEASE INDICATION |
    8. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    9. 6.6 CANADA MARKET ANALYSIS BY PRODUCT |
    10. 6.7 CANADA MARKET ANALYSIS BY DISEASE INDICATION |
    11. 6.8 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY PRODUCT |
    14. 6.11 GERMANY MARKET ANALYSIS BY DISEASE INDICATION |
    15. 6.12 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    16. 6.13 UK MARKET ANALYSIS BY PRODUCT |
    17. 6.14 UK MARKET ANALYSIS BY DISEASE INDICATION |
    18. 6.15 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    19. 6.16 FRANCE MARKET ANALYSIS BY PRODUCT |
    20. 6.17 FRANCE MARKET ANALYSIS BY DISEASE INDICATION |
    21. 6.18 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    22. 6.19 RUSSIA MARKET ANALYSIS BY PRODUCT |
    23. 6.20 RUSSIA MARKET ANALYSIS BY DISEASE INDICATION |
    24. 6.21 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    25. 6.22 ITALY MARKET ANALYSIS BY PRODUCT |
    26. 6.23 ITALY MARKET ANALYSIS BY DISEASE INDICATION |
    27. 6.24 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    28. 6.25 SPAIN MARKET ANALYSIS BY PRODUCT |
    29. 6.26 SPAIN MARKET ANALYSIS BY DISEASE INDICATION |
    30. 6.27 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY PRODUCT |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY DISEASE INDICATION |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY PRODUCT |
    36. 6.33 CHINA MARKET ANALYSIS BY DISEASE INDICATION |
    37. 6.34 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    38. 6.35 INDIA MARKET ANALYSIS BY PRODUCT |
    39. 6.36 INDIA MARKET ANALYSIS BY DISEASE INDICATION |
    40. 6.37 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    41. 6.38 JAPAN MARKET ANALYSIS BY PRODUCT |
    42. 6.39 JAPAN MARKET ANALYSIS BY DISEASE INDICATION |
    43. 6.40 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY PRODUCT |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY PRODUCT |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY DISEASE INDICATION |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    50. 6.47 THAILAND MARKET ANALYSIS BY PRODUCT |
    51. 6.48 THAILAND MARKET ANALYSIS BY DISEASE INDICATION |
    52. 6.49 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    53. 6.50 INDONESIA MARKET ANALYSIS BY PRODUCT |
    54. 6.51 INDONESIA MARKET ANALYSIS BY DISEASE INDICATION |
    55. 6.52 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY PRODUCT |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY DISEASE INDICATION |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY PRODUCT |
    61. 6.58 BRAZIL MARKET ANALYSIS BY DISEASE INDICATION |
    62. 6.59 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    63. 6.60 MEXICO MARKET ANALYSIS BY PRODUCT |
    64. 6.61 MEXICO MARKET ANALYSIS BY DISEASE INDICATION |
    65. 6.62 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY PRODUCT |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY DISEASE INDICATION |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE INDICATION |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY DISEASE INDICATION |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY DISEASE INDICATION |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY PRODUCT |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY DISEASE INDICATION |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY PRODUCT, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY DISEASE INDICATION, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY PRODUCT, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DISEASE INDICATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Product (USD Billion, 2025-2035)

  • Novel Oral Anticoagulants
  • Warfarin

Healthcare By Disease Indication (USD Billion, 2025-2035)

  • Atrial Fibrillation
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Heart Attacks

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions